Grow Your Pharma Business Digitally
Virtual Booth
Contact Supplier
An Enquiry
Product Reset all filters
01 1Pluvicto
Lutetium Lu 177 Vipivotide Tetraxetan
Novartis
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 1,392
2023 Revenue in Millions : 980
Growth (%) : 42
Portfolio PDF
Product Web Link
Digital Content
Website
Corporate PDF